07:02 AM EDT, 07/10/2025 (MT Newswires) -- Pfizer ( PFE ) and Astellas Pharma said Thursday that their phase 3 study of Xtandi plus leuprolide met a key secondary endpoint, showing a statistically significant and clinically meaningful improvement in overall survival in men with a type of prostate cancer.

The drugmakers said that Xtandi monotherapy showed a favorable trend toward improved overall survival, but it did not reach statistical significance compared to the placebo plus leuprolide arm.

Xtandi is already approved in over 80 countries, including the US, EU, and Japan, for various prostate cancer indications, they added.